Tocilizumab-induced Transaminitis in a Seropositive Rheumatoid Arthritis Patient with Macrophage Activation Syndrome / 이화의대지
The Ewha Medical Journal
;
: 23-27, 2016.
Article
in English
| WPRIM
| ID: wpr-147090
ABSTRACT
As a new humanized monoclonal antibody against the interleukin-6 receptor, tocilizumab is currently used for the treatment of rheumatoid arthritis (RA) patients. Tocilizumab was reported to provoke drug-related liver toxicity, although there have been no reports on significant liver toxicity from tocilizumab in Korean patients with RA to date. Here, we describe the first case of tocilizumab-related liver toxicity in a patient with complicated RA, accompanied with macrophage activation syndrome, who had received tacrolimus and prednisolone and in whom both conventional disease modifying anti-rheumatic drugs, including methotrexate, leflunomide and sulfasalazine or tumor necrotizing factor-alpha blockades, were contraindicated due to drug eruption and a history of lung cancer.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Arthritis, Rheumatoid
/
Sulfasalazine
/
Tranexamic Acid
/
Prednisolone
/
Methotrexate
/
Interleukin-6
/
Tacrolimus
/
Drug Eruptions
/
Antirheumatic Agents
/
Macrophage Activation Syndrome
Limits:
Humans
Language:
English
Journal:
The Ewha Medical Journal
Year:
2016
Type:
Article
Similar
MEDLINE
...
LILACS
LIS